Abstract 14932: Early Canadian Experience Using Selexipag as Part of an Oral Triple Therapy Regimen in Pediatric Patients With Severe Pulmonary Arterial Hypertension

Introduction: Use of prostacyclins in the treatment of severe pediatric pulmonary arterial hypertension (PAH) has increased significantly over the past three decades. Chronic IV or SC administratio...